Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.

21 Feb 2024

Innovative treatment increases survival of people with malignant mesothelioma, trial shows

An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.

15 Feb 2024

Combination therapy offers breakthrough in NSCLC treatment

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

13 Feb 2024

Medicaid expansion associated with reduction in early mortality after lung cancer surgery

In a new, national, hospital-based study, researchers at the American Cancer Society (ACS) found that Medicaid expansion was associated with a statistically significant reduction in early mortality following surgical resection of stage I-III non-small cell lung cancer (NSCLC).

16 Jan 2024

Study explores intratumoral microbiota as a novel frontier in cancer research

Researchers review the role of intratumoral microbiota in cancer development, suggesting its potential in predicting and treating various cancers.

14 Jan 2024

Radiation and chemo combo tackles advanced non-small cell lung cancer

A new study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center shows that using high doses of radiation while integrating an ablative radiotherapy technique called stereotactic ablative radiotherapy (SABR) concurrently with chemotherapy is safe and effective in treating people with locally advanced non-small cell lung cancer that is not suitable for surgery.

11 Jan 2024

Breakthrough drug halts lung cancer and brain metastases

D'Or Institute for Research and Education (IDOR) played an important role in the phase III LIBRETTO-431 multicenter study, which evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pembrolizumab (immune checkpoint inhibitor) in non-small cell lung cancer (NSCLC).

5 Jan 2024

Novel PET tracer accurately detects common cancer mutation for tailored treatment

A novel PET imaging tracer has been proven to safely and effectively detect a common cancer gene mutation that is an important molecular marker for tumor-targeted therapy.

2 Jan 2024

Blocking an allergy pathway unleashes antitumor immunity in mouse models of non-small cell lung cancer

Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).

6 Dec 2023

Lung-MAP: A beacon of hope for lung cancer patients

The unique public-private partnership that for almost a decade has undergirded the first National Cancer Institute (NCI)-sponsored precision medicine clinical trial in lung cancer can serve as a model for future clinical research that is more rapid, innovative, and inclusive.

1 Dec 2023

Research paves way for clinical trials of existing drugs for brain metastasis

The largest review of papers for brain cancer that has spread from the lungs has found abnormalities in the brain cancer and for which licensed drugs could be clinically trialled to find out if they could treat the disease.

29 Nov 2023

AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology

Cell Signaling Technology (CST), a life science biotechnology company and leading provider of antibodies, kits, and services, and Amoy Diagnostics Co., Ltd. (AmoyDx), a China-based innovative molecular diagnostics company in the field of precision oncology, announced today the expansion of their ongoing partnership for companion diagnostic (CDx) development in China.

From Cell Signaling Technology 23 Nov 2023

New study shows bivalent COVID-19 booster increases antibody response in lung cancer patients

Bivalent booster dose enhanced neutralization of Omicron XBB (sub)variants in non-small cell lung cancer (NSCLC) patients.

23 Nov 2023

Immunotherapy drug is safe and may benefit overall survival for patients with advanced NSCLC

For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new eClinicalMedicine study by UPMC Hillman Cancer Center researchers.

21 Nov 2023

New understanding of lung cancer cells' 'memories' suggests novel treatment approach

A new understanding of lung cancer cells' "memories" suggests a new strategy for improving treatment, Memorial Sloan Kettering Cancer Center (MSK) researchers have found.

17 Nov 2023

New pathologic scoring system could help predict survival in lung cancer patients

A new pathologic scoring system that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments can be used to predict survival, according to new research led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation Center for Advanced Genomics and Imaging at the Johns Hopkins University.

6 Nov 2023

Dato-DXd improves progression-free survival in patients with metastatic non-squamous NSCLC

Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement that was primarily driven by patients with non-squamous tumors.

26 Oct 2023

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.

24 Oct 2023

Lactobacillus iners in tumors: Driving chemoradiation resistance via lactate-induced metabolic rewiring

Investigating tumor and gut microbiome traits that impact chemoradiation therapy in patients with cervical cancer.